GTx, Inc. (NASDAQ:GTXI)
GTx, Inc. (NASDAQ:GTXI) represented a move of 2.84 percent or $-0.02 per share and closed its previous day trading session at $1.45. 735652 Shares were traded in the last trading session with an Average Volume of 2.32 Million Shares. The stock currently has a Market Capitalization of 33.9 Million.
GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. GTx’s lead candidate is enobosarm, a selective androgen receptor modulator, or SARM, targeted at the androgen receptor, or AR, in women with advanced breast cancer whose tumors express the androgen receptor and the estrogen receptor, or ER, and women with AR positive triple negative breast cancer. GTx is also evaluating enobosarm for the treatment of other serious medical conditions where building lean body mass is important.
The stock traded between $ 1.32 and $25.60 over 1-Year time period showing its price to sales ratio of 0. GTx, Inc. (NASDAQ:GTXI) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-28.42 and 200-Day Simple Moving Average of $-89.88. Its Price to Free Cash Flow is 0 and Price to Book of 1.12.
Analyst’s recommended the stock as 3 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, GTx, Inc. (NASDAQ:GTXI) reported its Actual EPS of $-0.39/share. The analysts offering Earnings Estimates for the company were believing that GTx, Inc. could bring EPS of $-0.3/share. The difference between Actual EPS and Estimated EPS was -0.09 Percent. Thus showing an Earnings Surprise of -30 Percent.
Penumbra, Inc. (NYSE:PEN)
In the last trading session, Penumbra, Inc. (NYSE:PEN) added its value by 1.08% closing at the price of $139.22. The stock currently has market capitalization of 4.75 Billion, with average volume of 345.53 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Penumbra, Inc. (NYSE:PEN) is showing beta of 0. This particular value of beta suggests that Penumbra, Inc. (NYSE:PEN) has historically moved 0% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Penumbra, Inc. (NYSE:PEN) is at $0.6.
The stock currently has RSI of 53.93. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company’s portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California.
Penumbra, Inc. (NYSE:PEN) topped its 52-week high price of $167.35 on 06/01/18 and 52-Week Low Price of $ 82.55 on 01/08/18. The Stock currently has P/E (price to earnings ttm) of 233.59 and Weekly volatility of 4.16% and monthly volatility of 5.41% respectively.